Journal article

A Novel Epigenetic Drug-Eluting Balloon Angioplasty Device: Evaluation in a Large Animal Model of Neointimal Hyperplasia

HongBin Liu, Melissa Byrne, Patrick Perlmutter, Ashley Walker, Gopal R Sama, Jegadesan Subbiah, Berkay Ozcelik, Robert E Widdop, Tracey A Gaspari, Keith Byron, Yung-Chih Chen, David M Kaye, Anthony E Dear

Cardiovascular Drugs and Therapy | Springer (part of Springer Nature) | Published : 2019


Purpose Drug-eluting balloon catheters (DEBc) coated with paclitaxel (PTX) have been associated with potential safety concerns. An efficacious but less toxic balloon coating may reduce these outcomes. We evaluated a novel DEBc, Epi-Solve, coated with metacept-3 (MCT-3), a member of the histone deacetylase inhibitor (HDACi) class of epigenetic agents, in a large animal model of neointimal hyperplasia (NIH). Methods Plain balloon angioplasty (PABA) catheters were ultrasonically coated with MCT-3 to generate Epi-Solve DEBc. An ovine model of NIH formation was established utilising partial left common carotid artery (LCA) ligation. Twenty-eight days post neointima (NI) induction, PABA, Epi-Solv..

View full abstract